SAFEs, 83(b) Elections, and Cap Table Hygiene
What to Get Right Before Your Series A
by
Teddy Ellison
Fundraising & Equity
Summary
An 83(b) election should be filed within 30 days of a restricted stock issuance. Missing the window is irreversible and the tax consequences compound for years. There are legal strategies to limit the exposure, but they take time and cost money. Separately, SAFE stacking creates dilution that does not appear in your cap table until a priced round forces the conversion math. For founders building at the AI and onchain intersection, both problems interact with token economics in ways that generic startup equity guides don't cover. The founders who walk into a Series A clean are the ones who ran the math before the term sheet arrived.
Many founders think they have done the equity formation work correctly on paper: Delaware C-corp, YC SAFEs for the pre-seed, standard four-year vesting. Fast forward 18 months later, when they present the cap table to a Series A lead and the mistakes begin to come to light..
The 83(b) election was filed late, or not at all. The SAFE conversion math was never modeled with all instruments outstanding. For founders planning a token, the equity and token economics have been running as separate spreadsheets that were never reconciled. Each of these is fixable before a priced round. The expensive version is finding out when a third party finds it first.
This covers what founders need to understand about equity mechanics, where standard formation advice stops being sufficient, and where the judgment call is harder than a template can handle.
83(b) elections: the 30-day filing window
Founder equity in a Delaware C-corp is almost always issued as restricted stock subject to vesting. The problem is that restricted stock is a taxable event under IRC Section 83(a) as the restrictions lapse, unless a founder makes an 83(b) election to accelerate the entire grant into the year of issuance.
Without the election, a founder recognizes ordinary income on each vesting tranche at fair market value on the vesting date. After a seed round, that means paying ordinary income tax on equity appreciation in a company they already built, on stock they cannot sell.
The fix is a one-page filing submitted to the IRS within 30 days of the stock grant, either by certified mail or through the IRS's online filing system. The IRS does not grant extensions, and the window runs from the date of issuance, not from the date it vests.
The most common version of this mistake is not a founder who knew about the filing and skipped it. It is a founder who incorporated through a formation service, received the documents, and assumed legal compliance was handled. Formation services typically do not file 83(b) elections, and some do not flag the deadline at all.
If the window has closed, there are potential remediation strategies, including amending the restricted stock agreement to make unvested shares transferable, modifying the company's repurchase rights, or surrendering the original grant in exchange for an alternate form of equity such as options or SARs. Each approach carries its own tax consequences and requires changes to the original deal terms. So while a missed 83(b) is not necessarily a dead end, the analysis on what to do next is specific to the founder's situation. And the sooner this analysis starts, the more options remain on the table.
Why standard 409A valuations break for AI and blockchain companies
An 83(b) election is only as good as the valuation it is pegged to. File at a nominal value and you have locked in a low tax basis on the full grant. File when fair market value is materially higher than you assumed, and you have a tax bill on phantom income.
A company with token treasury, an outstanding token warrant, or a planned TGE is a materially different fact pattern from a standard Delaware C-corp, and most 409A providers will not tell you they are not equipped for it. They apply their standard methodology and produce a number that does not hold up when the IRS or an investor's counsel examines it. The founder finds out at the worst possible time.
The consequences run in both directions. An understated 409A at the time of an 83(b) election creates ordinary income exposure on the difference between the filed value and actual fair market value. An overstated 409A means option grants are priced higher than necessary, which compounds as a recruitment and retention problem.
For founders who already received restricted stock during or after a token-related event, the question is whether the 409A that supported your 83(b) election accounted for the full picture. If it did not, the analysis of what that means for your tax position is not a self-serve exercise.
SAFE stacking: where the dilution math falls apart
A SAFE is a contractual right to receive equity at a future priced round. The YC post-money SAFE is the dominant instrument, and each one is straightforward in isolation. Most founders raising at the AI and onchain intersection do not raise one. They raise three or four over 18 to 24 months, from a mix of funds, angels, and accelerators, each with different caps and sometimes with side letters that nobody is tracking.
When the priced round arrives, every SAFE converts simultaneously, each calculating share count under its own terms, each drawing from the same post-money cap table. The dilution is not additive in the way founders expect when they model each instrument separately. It arrives all at once.
Many investors attach MFN provisions, pro-rata rights and information rights to their SAFEs via side letter. A founder who cannot account for every right attached to every outstanding instrument is going to have a slower diligence process than one who can, and slower at Series A has a dollar cost.
The side letter provision that causes the most friction heading into a priced round is the pro-rata or preemptive right. It reads as a standard ask at the SAFE stage and most founders sign it without pushback. The problem surfaces when a Series A lead wants to take a full allocation and discovers that three or four prior investors each hold a contractual right to participate, every one of whom needs to either exercise or waive before the lead's terms can close. The founders who resolve this fastest are the ones who inventoried every side letter obligation and started the waiver conversation before the term sheet arrived.
Sophisticated investors reconcile token economics with the equity cap table as a matter of course. They will ask whether any outstanding token warrant creates an equity-like claim that belongs in the fully diluted analysis. Founders who have not done this reconciliation before a financing process opens will do it during one, under deadline, with little leverage.
What Series A diligence looks like
Most founders have a general sense that Series A diligence involves lawyers reviewing their documents. Fewer understand what institutional investors are specifically looking for in cap tables, or what a problematic finding costs in practice.
The process typically opens with a request for a fully-diluted cap table, every financing instrument issued, and a representation that the cap table is accurate and complete. The investor's counsel will then reconstruct the cap table independently from the underlying instruments and compare it to what the founder presented.
The findings that surface most often are not obscure. Missed 83(b) elections, SAFE conversion math that does not match the founder's cap table, and token warrants missing from the fully diluted analysis are the three I see most consistently. Each one means the founder's ownership representation was inaccurate, and shifts the negotiating dynamic in the investor’s direction.
Deals do not typically die over a single clean-up item. They slow down the process and slow is expensive. Founders who move fastest through Series A diligence are the ones who have already reconstructed their own cap table before the process opens.
A framework for founders
Most of the expensive mistakes here do not come from founders who ignored the analysis. They arise when founders are moving too quickly or overlook details in their cap table that don’t account for the full picture.
Knowing which decisions require a lawyer, which require careful self-review, and which are genuinely straightforward is what keeps this gap from opening in the first place. Our Tech Founder's DIY Legal Guide offers a general framework for how to approach these decisions, which we’ve translated to some guidance on cap table hygiene below.
What founders can handle themselves
You don't need a lawyer to file your 83(b) election, model your SAFE conversion, or keep a current cap table. The 83(b) mechanics are public: certified mail to the IRS service center for your state within 30 days of your grant, return receipt requested, signed copy retained, copy filed with your tax return. The cost is postage.
Run the full SAFE conversion scenario before any priced round, with every outstanding instrument converting simultaneously against the same post-money cap table. Most founders who have been surprised by their Series A dilution never ran this model. Run it before you are in the room with a term sheet.
Keep a current fully-diluted cap table that accounts for every instrument outstanding, including token-related obligations that create equity-like claims. If producing that document takes more than an hour, the hygiene work is behind.
Where it gets complicated
Legal support becomes important when the instruments you have signed start to diverge from standard, and at the AI and onchain intersection they frequently do.
A SAFE with a side letter needs to be reviewed against every other outstanding instrument before the priced round. Many founders have not read their side letters since signing, and the interaction between MFN provisions and new round terms is not visible in the individual SAFE. A 409A on a company with material token exposure needs a provider who has done this specific analysis before, because the standard methodology is not a safe harbor on a non-standard fact pattern.
Token economics and equity cap table reconciliation belong here too. Presenting them as separate documents to a Series A lead is not a strategy. It is a gap the investor's counsel will close for you.
Where expert counsel becomes mandatory
Outside counsel earns its place when the exposure cannot be assessed without knowing the specific interaction of your instruments, your token situation, and the proposed terms.
A missed 83(b) election requires someone who has worked through the mitigation options and knows how to represent the exposure to incoming investors. SAFE stacks with side letters that interact with new round terms, and 409A valuations that did not account for token exposure, belong in the same category. Serotonin Legal's work at this stage is identifying and resolving these issues before the term sheet is signed, not after the investor's counsel has found them.
Final Thoughts
The equity decisions covered in this post are not complicated in isolation. The 83(b) filing is a one-page document. SAFE conversion math is not opaque. A fully diluted cap table that accounts for every outstanding instrument, including token-related obligations, is work any founder can do before a financing process opens. What makes these decisions expensive is not their complexity. It is that they interact with each other at the worst possible moment, and they do it invisibly until a third party runs the numbers.
Serotonin Legal advises technology founders on corporate, regulatory, and transactional matters at the intersection of AI, blockchain, and fintech. This guide is for general informational purposes and does not constitute legal advice. No attorney-client relationship is formed by reading this material.
FAQs
What is an 83(b) election and what happens if I miss it?
An 83(b) election is a one-page IRS filing that lets founders pay tax on restricted stock at the time of grant, when the company's value is typically nominal, rather than as shares vest over time. If you miss the 30-day filing window, you pay ordinary income tax on each vesting tranche at fair market value as it vests instead. The IRS does not grant extensions under any circumstances, and the election cannot be made retroactively once the window closes. This means once a company has raised a seed round, that fair market value is no longer nominal and founders may end up with a tax bill on appreciation in a company they already built, on stock they cannot yet sell.
How do I file an 83(b) election?
File a completed 83(b) statement by certified mail or online to the IRS service center for your state within 30 days of your stock grant, with return receipt requested. Retain a signed copy for your records and include a copy with your federal tax return for the year of the grant. The IRS does not confirm receipt, which is why the mailing documentation matters. Most formation services do not handle this filing, and many do not flag the deadline. If you incorporated recently and are not certain whether it was filed, that is the first thing to check.
What is a SAFE note and how does it convert?
A SAFE (Simple Agreement for Future Equity) is a contractual right to receive equity at a future priced round. It is not debt, it does not accrue interest, and it has no maturity date. The YC post-money SAFE is now standard. It converts at the next priced round at a valuation cap or discount, whichever produces more shares for the investor. Where founders consistently get into trouble is with multiple SAFEs converting simultaneously: each calculates its share count under its own terms against the same post-money cap table, and the combined dilution is not what they modeled when they looked at each instrument individually.
What are the most common SAFE dilution mistakes founders make?
Modeling each SAFE in isolation is the primary one. A founder who raised three SAFEs at different caps over 18 months has a dilution math problem that only becomes visible when all three convert simultaneously at the priced round. The second mistake is not tracking side letters. Institutional blockchain funds frequently attach MFN provisions or pro-rata rights to their SAFEs, and those rights interact with new round terms in ways that are not visible in the individual SAFE. By the time a Series A lead's counsel has reconstructed the full cap table from the underlying instruments, the founder is correcting a representation under deadline rather than presenting accurate information.
What cap table issues typically surface in Series A diligence for AI and onchain companies?
The three I see most consistently: missed 83(b) elections creating ordinary income tax exposure on unvested equity, SAFE conversion math that does not match the founder's presented cap table (usually because side letters were not reflected), and token warrants that were not disclosed or not included in the fully diluted analysis. Each one means a founder's ownership representation was inaccurate. Most are resolvable before a process opens. The cost of resolving them during diligence is measured in deal terms and time, and in competitive processes, it can affect whether the deal closes at all.
Curious to learn more about Serotonin Legal? —
Get in Touch
SAFEs, 83(b) Elections, and Cap Table Hygiene
What to Get Right Before Your Series A
by
Teddy Ellison
Fundraising & Equity
Summary
An 83(b) election should be filed within 30 days of a restricted stock issuance. Missing the window is irreversible and the tax consequences compound for years. There are legal strategies to limit the exposure, but they take time and cost money. Separately, SAFE stacking creates dilution that does not appear in your cap table until a priced round forces the conversion math. For founders building at the AI and onchain intersection, both problems interact with token economics in ways that generic startup equity guides don't cover. The founders who walk into a Series A clean are the ones who ran the math before the term sheet arrived.
Many founders think they have done the equity formation work correctly on paper: Delaware C-corp, YC SAFEs for the pre-seed, standard four-year vesting. Fast forward 18 months later, when they present the cap table to a Series A lead and the mistakes begin to come to light..
The 83(b) election was filed late, or not at all. The SAFE conversion math was never modeled with all instruments outstanding. For founders planning a token, the equity and token economics have been running as separate spreadsheets that were never reconciled. Each of these is fixable before a priced round. The expensive version is finding out when a third party finds it first.
This covers what founders need to understand about equity mechanics, where standard formation advice stops being sufficient, and where the judgment call is harder than a template can handle.
83(b) elections: the 30-day filing window
Founder equity in a Delaware C-corp is almost always issued as restricted stock subject to vesting. The problem is that restricted stock is a taxable event under IRC Section 83(a) as the restrictions lapse, unless a founder makes an 83(b) election to accelerate the entire grant into the year of issuance.
Without the election, a founder recognizes ordinary income on each vesting tranche at fair market value on the vesting date. After a seed round, that means paying ordinary income tax on equity appreciation in a company they already built, on stock they cannot sell.
The fix is a one-page filing submitted to the IRS within 30 days of the stock grant, either by certified mail or through the IRS's online filing system. The IRS does not grant extensions, and the window runs from the date of issuance, not from the date it vests.
The most common version of this mistake is not a founder who knew about the filing and skipped it. It is a founder who incorporated through a formation service, received the documents, and assumed legal compliance was handled. Formation services typically do not file 83(b) elections, and some do not flag the deadline at all.
If the window has closed, there are potential remediation strategies, including amending the restricted stock agreement to make unvested shares transferable, modifying the company's repurchase rights, or surrendering the original grant in exchange for an alternate form of equity such as options or SARs. Each approach carries its own tax consequences and requires changes to the original deal terms. So while a missed 83(b) is not necessarily a dead end, the analysis on what to do next is specific to the founder's situation. And the sooner this analysis starts, the more options remain on the table.
Why standard 409A valuations break for AI and blockchain companies
An 83(b) election is only as good as the valuation it is pegged to. File at a nominal value and you have locked in a low tax basis on the full grant. File when fair market value is materially higher than you assumed, and you have a tax bill on phantom income.
A company with token treasury, an outstanding token warrant, or a planned TGE is a materially different fact pattern from a standard Delaware C-corp, and most 409A providers will not tell you they are not equipped for it. They apply their standard methodology and produce a number that does not hold up when the IRS or an investor's counsel examines it. The founder finds out at the worst possible time.
The consequences run in both directions. An understated 409A at the time of an 83(b) election creates ordinary income exposure on the difference between the filed value and actual fair market value. An overstated 409A means option grants are priced higher than necessary, which compounds as a recruitment and retention problem.
For founders who already received restricted stock during or after a token-related event, the question is whether the 409A that supported your 83(b) election accounted for the full picture. If it did not, the analysis of what that means for your tax position is not a self-serve exercise.
SAFE stacking: where the dilution math falls apart
A SAFE is a contractual right to receive equity at a future priced round. The YC post-money SAFE is the dominant instrument, and each one is straightforward in isolation. Most founders raising at the AI and onchain intersection do not raise one. They raise three or four over 18 to 24 months, from a mix of funds, angels, and accelerators, each with different caps and sometimes with side letters that nobody is tracking.
When the priced round arrives, every SAFE converts simultaneously, each calculating share count under its own terms, each drawing from the same post-money cap table. The dilution is not additive in the way founders expect when they model each instrument separately. It arrives all at once.
Many investors attach MFN provisions, pro-rata rights and information rights to their SAFEs via side letter. A founder who cannot account for every right attached to every outstanding instrument is going to have a slower diligence process than one who can, and slower at Series A has a dollar cost.
The side letter provision that causes the most friction heading into a priced round is the pro-rata or preemptive right. It reads as a standard ask at the SAFE stage and most founders sign it without pushback. The problem surfaces when a Series A lead wants to take a full allocation and discovers that three or four prior investors each hold a contractual right to participate, every one of whom needs to either exercise or waive before the lead's terms can close. The founders who resolve this fastest are the ones who inventoried every side letter obligation and started the waiver conversation before the term sheet arrived.
Sophisticated investors reconcile token economics with the equity cap table as a matter of course. They will ask whether any outstanding token warrant creates an equity-like claim that belongs in the fully diluted analysis. Founders who have not done this reconciliation before a financing process opens will do it during one, under deadline, with little leverage.
What Series A diligence looks like
Most founders have a general sense that Series A diligence involves lawyers reviewing their documents. Fewer understand what institutional investors are specifically looking for in cap tables, or what a problematic finding costs in practice.
The process typically opens with a request for a fully-diluted cap table, every financing instrument issued, and a representation that the cap table is accurate and complete. The investor's counsel will then reconstruct the cap table independently from the underlying instruments and compare it to what the founder presented.
The findings that surface most often are not obscure. Missed 83(b) elections, SAFE conversion math that does not match the founder's cap table, and token warrants missing from the fully diluted analysis are the three I see most consistently. Each one means the founder's ownership representation was inaccurate, and shifts the negotiating dynamic in the investor’s direction.
Deals do not typically die over a single clean-up item. They slow down the process and slow is expensive. Founders who move fastest through Series A diligence are the ones who have already reconstructed their own cap table before the process opens.
A framework for founders
Most of the expensive mistakes here do not come from founders who ignored the analysis. They arise when founders are moving too quickly or overlook details in their cap table that don’t account for the full picture.
Knowing which decisions require a lawyer, which require careful self-review, and which are genuinely straightforward is what keeps this gap from opening in the first place. Our Tech Founder's DIY Legal Guide offers a general framework for how to approach these decisions, which we’ve translated to some guidance on cap table hygiene below.
What founders can handle themselves
You don't need a lawyer to file your 83(b) election, model your SAFE conversion, or keep a current cap table. The 83(b) mechanics are public: certified mail to the IRS service center for your state within 30 days of your grant, return receipt requested, signed copy retained, copy filed with your tax return. The cost is postage.
Run the full SAFE conversion scenario before any priced round, with every outstanding instrument converting simultaneously against the same post-money cap table. Most founders who have been surprised by their Series A dilution never ran this model. Run it before you are in the room with a term sheet.
Keep a current fully-diluted cap table that accounts for every instrument outstanding, including token-related obligations that create equity-like claims. If producing that document takes more than an hour, the hygiene work is behind.
Where it gets complicated
Legal support becomes important when the instruments you have signed start to diverge from standard, and at the AI and onchain intersection they frequently do.
A SAFE with a side letter needs to be reviewed against every other outstanding instrument before the priced round. Many founders have not read their side letters since signing, and the interaction between MFN provisions and new round terms is not visible in the individual SAFE. A 409A on a company with material token exposure needs a provider who has done this specific analysis before, because the standard methodology is not a safe harbor on a non-standard fact pattern.
Token economics and equity cap table reconciliation belong here too. Presenting them as separate documents to a Series A lead is not a strategy. It is a gap the investor's counsel will close for you.
Where expert counsel becomes mandatory
Outside counsel earns its place when the exposure cannot be assessed without knowing the specific interaction of your instruments, your token situation, and the proposed terms.
A missed 83(b) election requires someone who has worked through the mitigation options and knows how to represent the exposure to incoming investors. SAFE stacks with side letters that interact with new round terms, and 409A valuations that did not account for token exposure, belong in the same category. Serotonin Legal's work at this stage is identifying and resolving these issues before the term sheet is signed, not after the investor's counsel has found them.
Final Thoughts
The equity decisions covered in this post are not complicated in isolation. The 83(b) filing is a one-page document. SAFE conversion math is not opaque. A fully diluted cap table that accounts for every outstanding instrument, including token-related obligations, is work any founder can do before a financing process opens. What makes these decisions expensive is not their complexity. It is that they interact with each other at the worst possible moment, and they do it invisibly until a third party runs the numbers.
Serotonin Legal advises technology founders on corporate, regulatory, and transactional matters at the intersection of AI, blockchain, and fintech. This guide is for general informational purposes and does not constitute legal advice. No attorney-client relationship is formed by reading this material.
FAQs
What is an 83(b) election and what happens if I miss it?
An 83(b) election is a one-page IRS filing that lets founders pay tax on restricted stock at the time of grant, when the company's value is typically nominal, rather than as shares vest over time. If you miss the 30-day filing window, you pay ordinary income tax on each vesting tranche at fair market value as it vests instead. The IRS does not grant extensions under any circumstances, and the election cannot be made retroactively once the window closes. This means once a company has raised a seed round, that fair market value is no longer nominal and founders may end up with a tax bill on appreciation in a company they already built, on stock they cannot yet sell.
How do I file an 83(b) election?
File a completed 83(b) statement by certified mail or online to the IRS service center for your state within 30 days of your stock grant, with return receipt requested. Retain a signed copy for your records and include a copy with your federal tax return for the year of the grant. The IRS does not confirm receipt, which is why the mailing documentation matters. Most formation services do not handle this filing, and many do not flag the deadline. If you incorporated recently and are not certain whether it was filed, that is the first thing to check.
What is a SAFE note and how does it convert?
A SAFE (Simple Agreement for Future Equity) is a contractual right to receive equity at a future priced round. It is not debt, it does not accrue interest, and it has no maturity date. The YC post-money SAFE is now standard. It converts at the next priced round at a valuation cap or discount, whichever produces more shares for the investor. Where founders consistently get into trouble is with multiple SAFEs converting simultaneously: each calculates its share count under its own terms against the same post-money cap table, and the combined dilution is not what they modeled when they looked at each instrument individually.
What are the most common SAFE dilution mistakes founders make?
Modeling each SAFE in isolation is the primary one. A founder who raised three SAFEs at different caps over 18 months has a dilution math problem that only becomes visible when all three convert simultaneously at the priced round. The second mistake is not tracking side letters. Institutional blockchain funds frequently attach MFN provisions or pro-rata rights to their SAFEs, and those rights interact with new round terms in ways that are not visible in the individual SAFE. By the time a Series A lead's counsel has reconstructed the full cap table from the underlying instruments, the founder is correcting a representation under deadline rather than presenting accurate information.
What cap table issues typically surface in Series A diligence for AI and onchain companies?
The three I see most consistently: missed 83(b) elections creating ordinary income tax exposure on unvested equity, SAFE conversion math that does not match the founder's presented cap table (usually because side letters were not reflected), and token warrants that were not disclosed or not included in the fully diluted analysis. Each one means a founder's ownership representation was inaccurate. Most are resolvable before a process opens. The cost of resolving them during diligence is measured in deal terms and time, and in competitive processes, it can affect whether the deal closes at all.
Curious to learn more about Serotonin Legal?
Get in Touch
